

State the number of shares outstanding of each of the registrant's classes of common equity, as of the latest practicable date: 28,625,164 shares issued and outstanding as of February 5, 2007.

GAMMACAN INTERNATIONAL, INC.**FORM 10-QSB****TABLE OF CONTENTS**

	Page No.
PART I	
Item 1. Financial Statements	1
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operation	14
Item 3. Controls And Procedures	21
PART II	
Item 1. Legal Proceedings	22
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3. Defaults Upon Senior Securities	22
Item 4. Submission of Matters to a Vote of Security Holders	22
Item 5. Other Information	22
Item 6. Exhibits	23

Forward Looking Statements

This Form 10-QSB includes a number of forward-looking statements that reflect management's current views with respect to future events and financial performance. Those statements include statements regarding the intent, belief or current expectations of GammaCan and members of its management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Readers are urged to carefully review and consider the various disclosures made in this report and in our other reports filed with the Securities and Exchange Commission. Important factors currently known to Management could cause actual results to differ materially from those in forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time. GammaCan believes that its assumptions are based upon reasonable data derived from and known about its business and operations and the business and operations of GammaCan. No assurances are made that actual results of operations or the results of GammaCan's future activities will not differ materially from its assumptions.

ITEM 1. - FINANCIAL STATEMENTS

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)
INTERIM FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2006

TABLE OF CONTENTS

	Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:	
Balance sheets	2
Statements of operations	3
Statements of changes in stockholders' equity	4
Statements of cash flows	5
Notes to financial statements	6-13

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

CONDENSED CONSOLIDATED BALANCE SHEETS
(US \$, except share data)

	December 31, 2006 (Unaudited)	September 30, 2006 (Audited)
A s s e t s		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 516,545	\$ 538,738
Prepaid expenses	33,750	-
Other	8,010	12,494
T o t a l current assets	558,305	551,232
FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT		
	26,735	21,071
LONG TERM DEPOSITS	18,791	22,270
PROPERTY AND EQUIPMENT, NET	23,748	25,247
T o t a l assets	\$ 627,579	\$ 619,820
Liabilities and stockholders' equity		
CURRENT LIABILITIES:		
Accounts payable	\$ 383,956	\$ 279,857
Convertible promissory note	353,145	-
Payroll and related accruals	57,637	49,242
T o t a l current liabilities	794,738	329,099
LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT	38,339	31,531
STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY):		
Preferred stock, \$ 0.0001 par value (20,000,000 shares authorized; none issued and outstanding)		
Common stock, \$ 0.0001 par value (100,000,000 authorized shares; 28,496,590 and 28,453,732 shares issued and outstanding as of December 31, 2006 and September 30, 2006, respectively)	2,849	2,845
Additional paid-in capital	3,515,007	3,172,284
Warrants	861,474	861,474
Deficit accumulated during the development stage	(4,584,828)	(3,777,413)
T o t a l stockholders' equity (capital deficiency)	(205,498)	259,190
T o t a l liabilities and stockholders' equity	\$ 627,579	\$ 619,820

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL INC.

(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(US \$, except share data)

	Three months ended December 31		Period from October 6, 1998* through December 31, 2006
	2006 (Unaudited)	2005 (Unaudited)	(Unaudited)
RESEARCH AND DEVELOPMENT COSTS	\$ 167,972	\$ 225,161	\$ 1,683,146
GENERAL AND ADMINISTRATIVE EXPENSES	632,866	212,775	2,921,577
OPERATING LOSS	800,838	437,936	4,604,723
FINANCIAL INCOME	(4,827)	(8,058)	(69,660)
FINANCIAL EXPENSES	7,048	3,036	29,162
LOSS BEFORE TAXES ON INCOME	803,059	432,914	4,564,225
TAXES ON INCOME	4,356	-	32,978
LOSS FROM OPERATIONS OF THE COMPANY AND ITS CONSOLIDATED SUBSIDIARY	807,415	432,914	4,597,203
MINORITY INTERESTS IN LOSSES OF A SUBSIDIARY	-	-	(12,375)
NET LOSS FOR THE PERIOD	\$ (807,415)	\$ (432,914)	\$ (4,584,828)
BASIC AND DILUTED LOSS PER COMMON SHARES	\$ (0.028)	\$ (0.016)	
WEIGHTED AVERAGE NUMBER OF COMMON SHARES USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON SHARE	28,475,161	26,847,065	

* Incorporation date, see note 1a.

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL INC. AND SUBSIDIARY
(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(CAPITAL DEFICIENCY)
(US \$, except share data)

	Number of Shares	Common Stock Amount	Warrants	Additional paid-in capital	Deficit accumulated during development stage	Total
Changes during the period from October 6, 1998 (date of incorporation) to September 30, 2004 (audited)						
Common stock and warrants issued for cash	57,506,498	\$ 5,750	\$ 139,494	\$ 782,141	-	\$ 927,385
Contributed capital				7,025		7,025
Cancellation of shares at June 8, 2004	(32,284,988)	(3,228)		3,228		
Gain on issuance of subsidiary stock to third party				86,625		86,625
Stock based compensation				62,600		62,600
Net loss					(514,086)	(514,086)
Balance at September 30, 2004 (audited)	25,221,510	2,522	139,494	941,619	(514,086)	569,549
Common stock and warrants issued for cash on November 11, 2004, net of issuance costs	978,000	97	367,892	766,630		1,134,619
Common stock and warrants issued for cash on January 25, 2005, net of issuance costs	32,000	3	12,037	24,760		36,800
Issuance of warrants to Consultants'				34,592		34,592
Net loss					(1,198,532)	(1,198,532)
	26,231,510	2,622	519,423	1,767,601	(1,712,618)	577,028

**Balance at September
30, 2005 (audited)**

Common stock and warrants issued for cash on October 31, 2005, net of issuance costs	666,666	67	72,410	365,670		438,147
Common stock and warrants issued for cash on December 20, 2005, net of issuance costs	1,555,556	156	269,641	804,998		1,074,795
Employees and consultants stock based compensation expenses				234,015		234,015
Net loss					(2,064,795)	(2,064,795)
Balance at September 30, 2006 (audited)	28,453,732	2,845	861,474	3,172,284	(3,777,413)	259,190
Common stock issued for services	*42,858	4		29,996		30,000
Employees and consultants stock based compensation expenses				312,727		312,727
Net loss					(807,415)	(807,415)
Balance at December 31, 2006 (unaudited)	28,496,590 \$	2,849 \$	861,474 \$	3,515,007 \$	(4,584,828) \$	(205,498)

*The Company issued a total of 171,432 shares. Shares presented in the statement above represent issued shares in respect of services received in the three months ended December 31, 2006 (see also Note 4(b)).

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL INC. AND SUBSIDIARY
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(US \$)

	Three months ended December 31,		Period from October 6, 1998* to December 31, 2006
	2006	2005	2006
	Unaudited	Unaudited	Unaudited
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net loss for the period	\$ (807,415)	\$ (432,914)	\$ (4,584,828)
Adjustments required to reconcile net loss to net cash used in operating activities:			
Income and expenses not involving cash flows:			
Depreciation	2,075	843	8,967
Common stock issued for services	30,000	-	33,000
Minority interests in losses of a subsidiary	-	-	(12,375)
Write off of in process research and development	-	-	100,000
Employees and consultants stock based compensation expenses	312,727	34,190	606,876
Increase in liability for employee rights upon retirement	6,808	(2,709)	38,339
Changes in operating assets and liabilities:			
Increase in prepaid expenses	(33,750)	(39,405)	(33,750)
Decrease (increase) in other current assets	7,755	(3,829)	(8,010)
Increase in current liabilities	115,639	173,070	443,738
Net cash used in operating activities	(366,161)	(270,754)	(3,408,043)
CASH FLOWS FROM INVESTING ACTIVITIES			
-			
Decrease (increase) in long term deposits	208	(1,637)	(18,791)
Funds in respect of employee rights upon retirement	(5,664)	644	(26,735)
Purchase of property and equipment	(576)	(384)	(32,715)
Net cash used in investing activities	(6,032)	(1,377)	(78,241)
CASH FLOWS FROM FINANCING ACTIVITIES:			
Issuance of convertible promissory note	350,000		350,000
Issuance of common stock and warrants net of issuance costs		1,550,000	3,652,829
Net cash provided by financing activities	350,000	1,550,000	4,002,829
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(22,193)	1,277,869	516,545
BALANCE OF CASH AND CASH EQUIVALENTS AT			

BEGINNING OF PERIOD	538,738	713,342		
BALANCE OF CASH AND CASH EQUIVALENTS				
AT END OF PERIOD	\$ 516,545	\$ 1,991,211	\$	516,545

* Incorporation date, see note 1a.

The accompanying notes are an integral part of the financial statements.

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

a.

General:

GammaCan International Inc. (A Development Stage Company; "the Company") was incorporated on October 6, 1998, under the laws of the State of Delaware, under the name of San Jose International, Inc. The Company has no significant revenues and in accordance with Statement of financial Accounting Standard ("SFAS") No. 7 "Accounting and Reporting by Development Stage enterprises", the Company is considered a development stage company.

On August 19, 2004, the name of the company was changed from "San Jose International, Inc." into "GammaCan International, Inc."

At this point in the development stage, the company's focus is to demonstrate efficacy of IgG cancer immunotherapy in human clinical trials. In July 2005, the company commenced Phase 2 clinical trials in humans to demonstrate clinical efficacy of IgG immunotherapy in three major cancers: colon, prostate and melanoma. These Phase 2 clinical trials are being conducted at three medical centers in Israel and results are anticipated during 2007. Following analysis and publication of the results the Company will decide on how to proceed with its future clinical work regarding the use of IgG. The decision will be based on several factors including the ability to attract strategic partners for co-development.

The Company is in the process of applying for an IND with the US FDA for VitiGam, the Company's second generation IgG product and first-in-class anti-cancer immunotherapy. VitiGam is slated to enter the clinic under a US IND in the near future. VitiGam is designed to target metastatic melanoma patients with Stage III and IV melanoma.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has net losses for the period from inception (October 6, 1998) through December 31, 2006 of \$4,584,828, as well as negative cash flow from operating activities. Presently, the company does not have sufficient cash resources to meet its requirements in the twelve months following January 1, 2007. These factors raise substantial doubt about the company's ability to continue as a going concern. Management is in the process of evaluating various financing alternatives as the Company will need to finance future research and development activities and general and administrative expenses through fund raising in the public or private equity markets. Although there is no assurance that the Company will be successful with those initiatives, management is confident that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors and existing shareholders.

These financial statements do not include any adjustments that may be necessary should the company be unable to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability.

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (continued):

b. Accounting principles

The accompanying unaudited financial statements of the Company and the subsidiary GammaCan Ltd. ("the Subsidiary") have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-QSB and Item 310 of Regulation S-B. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three-month period ended December 30, 2006, are not necessarily indicative of the results that may be expected for the year ended September 30, 2007. For further information, refer to the financial statements and footnotes thereto included in the consolidated annual report on Form 10-KSB for the year ended September 30, 2006.

c. Use of estimates in the preparation of financial statements

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statement date and the reported expenses during the reporting periods. Actual results could differ from those estimates.

d. Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiary GammaCan Ltd. All material intercompany transactions and balances have been eliminated in consolidation.

e. Cash equivalents

The company considers all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.

f. Loss per share

Basic and diluted net losses per common share are presented in accordance with FAS No. 128 "Earning per share" ("FAS128"), for all periods presented. Outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stocks options and warrants excluded from the calculations of diluted net loss was 6,317,775 for the three months ended December 31, 2006 (3,967,775 for the three months ended December 31, 2005).

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (continued):

g. Stock based compensation

On August 17, 2004, the company's board of directors adopted the 2004 Employees and Consultants Stock Option Plan (hereafter - the Stock Option Plan). Under the Plan 5,000,000 shares have been reserved for the grant of options, which may be issued at the discretion of the Company's board of directors from time to time. Under this Plan, each option is exercisable to purchase one common share of \$0.0001 par value of the Company.

The options may be exercised after vesting and only in accordance with the following:

1. On the first anniversary commencing the grant date - 25% of the options.
2. On the last day of each of the 36 months following the first anniversary of the grant date, the remaining options shall vest in equal monthly installments.

The maximum term of the option is 10 years.

A summary of the status of the company's plan as of December 31, 2006, and changes during the three months period ending on this date, is presented below:

	Number	Three months ended December 31, 2006 Weighted average exercise price \$
<u>For options granted to employees:</u>		
Options outstanding at beginning of the period	2,830,000	\$ 1.24
Changes during the period:		
Granted - at market price	300,000	0.45
Granted - at an exercise price less than market price	-	-
Exercised	-	-
Forfeited	-	-
Expired	-	-
Options outstanding at end of the period	3,130,000	1.16
Options exercisable at end of the period	282,708	
Weighted average fair value of options granted during the period	\$ 0.37	

The following table presents summary information concerning the options outstanding as of December 31, 2006:

Range	Options outstanding		Weighted average	Options exercisable	
	Number outstanding	Weighted average		Number exercisable	Weighted average

Edgar Filing: GAMMACAN INTERNATIONAL INC - Form 10QSB

of exercise prices \$	at December 31, 2006	remaining contractual life Years	exercise price \$	at December 31, 2006	exercise price \$
0.45 to 0.93	300,000	9.85	0.45	-	-
0.93 to 1.37	2,830,000	9.10	1.24	282,708	1.12

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (continued):

Unrecognized compensation as determined under FAS 123R as of December 31, 2006 totaled \$1,924,230, to be depreciated over the next 39 months.

Until September 30, 2006 the Company accounted for employee stock based compensation in accordance with Accounting Principles Board Opinion No. 25 "Accounting for Stock Issued to Employees" ("APB 25") and related interpretations. In accordance with FAS 123 - "Accounting for Stock-Based Compensation" ("FAS 123"), the Company disclosed pro forma data assuming the Company had accounted for employee stock option grants using the fair value-based method defined in FAS 123.

On October 1, 2006 the Company adopted the revised Statement of Financial Accounting Standards ("FAS") No. 123, Share-Based Payment (FAS 123R), which addresses the accounting for share-based payment transactions in which the Company obtains employee services in exchange for (a) equity instruments of the Company or (b) liabilities that are based on the fair value of the Company's equity instruments or that may be settled by the issuance of such equity instruments. FAS 123R eliminates the ability to account for employee share-based payment transactions using APB Opinion No. 25, Accounting for Stock Issued to Employees, and requires instead that such transactions be accounted for using the grant-date fair value based method. This Statement is effective as of the beginning of the first annual reporting period that begins after December 15, 2005, for small business issuers, which is October 1, 2006 for the Company.

This Statement applies to all awards granted or modified after the Statement's effective date. In addition, compensation cost for the unvested portion of previously granted awards that remain outstanding on the Statement's effective date shall be recognized on or after the effective date, as the related services are rendered, based on the awards' grant-date fair value as previously calculated for the pro-forma disclosure under FAS 123.

The Company applied the modified prospective application transition method, as permitted by the Statement. Under such transition method, upon the adoption of FAS 123R, the Company's financial statements for periods prior to the effective date of the Statement is not restated.

The company accounts for equity instruments issued to third party service providers (non-employees) in accordance with the fair value based on an option-pricing model, pursuant to the guidance in EITF 96-18 "Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling Goods or Services". The fair value of the options granted is revalued over the related service periods and recognized using the accelerated method.

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (continued):

The following table illustrates the pro - forma effect on net loss and loss per common share assuming the Company had applied the fair value recognition provisions of FAS 123 to its stock-based employee:

	Three months ended December 31, 2005
Net loss as reported	\$ (432,914)
Deduct: Stock based employee compensation expense included in net loss as reported	4,365
Add: pro forma stock based employee compensation expense determined under fair value method for all awards, net of related tax effects	(62,726)
Recognize the reversal of the pro forma stock based employee compensation expense determined under fair value method due to forfeiture of awards granted to employees	79,676
Pro forma net loss	\$ (411,599)
Net loss per common shares:	
Basic and diluted loss per share - as reported	\$ (0.016)
Basic and diluted loss per share - pro forma	\$ (0.015)

h. Recently issued accounting pronouncements

1. In July 2006, the FASB issued FASB Interpretation (FIN) No. 48 "Accounting for Uncertainty in Income Taxes" (FIN 48). FIN 48 prescribes a comprehensive model for recognizing, measuring, presenting and disclosing in the financial statements tax positions taken or expected to be taken on a tax return, including a decision whether to file or not to file in a particular jurisdiction. FIN 48 is effective for fiscal years beginning after December 15, 2006 (year beginning October 1, 2007 for the Company). If there are changes in net assets as a result of application of FIN 48 these will be accounted for as an adjustment to retained earnings. In the Company's opinion, implementation of this standard is not expected to have a material effect on its financial statements in future periods.

2. In September 2006, the FASB issued Statement of Financial Accounting Standard (SFAS) No. 157, "Fair Value Measurements" ("FAS 157"). FAS 157 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS No. 157 will apply whenever another standard requires (or permits) assets or liabilities to be measured at fair value. The standard does not expand the use of fair value to any new circumstances. SFAS No. 157 is effective for

financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years, which is the year beginning October 1, 2008 for the company.

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES (continued):

3. In September 2006, the Financial Accounting Standards Board (the "FASB") issued Statement of Financial Accounting Standard No. 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans" (FAS 158). FAS 158 requires employers to fully recognize the obligations associated with single-employer defined benefit pension, retiree healthcare and other postretirement plans in their financial statements. The provisions of FAS 158 are effective as of the end of the fiscal year ending after December 15, 2006, which is the year beginning October 1, 2007 for the Company. In the Company's opinion, implementation of this standard is not expected to have a material effect on its financial statements in future periods.

i. Reclassifications

Certain figures in respect of prior years have been reclassified to conform to the current year presentation.

NOTE 2 - LONG TERM DEPOSITS:

Amount represents deposits in respect of lease agreements for the company's office facilities and vehicles used by its employees.

NOTE 3 - CONVERTIBLE PROMISSORY NOTE:

On November 20, 2006 the Company issued a convertible promissory note, in a principal amount of \$350,000, which bears interest at 8% payable on maturity of the note and matures on November 20, 2007. At the discretion of the lender, in the event that the Company raises debt or equity financing during the 12 month period following the issuance of the note, the principal and interest due under the note is convertible on the same terms as such financing.

The option to convert the amount into equity is measured by its fair value. The fair value allocated to the option estimated by using the Black Scholes option-pricing model is \$109,705. The value was based on the following assumptions: dividend yield of 0%; expected volatility of 90%; risk-free interest rates of 5.2%; and expected lives of 0.7 years.

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 4 - STOCK TRANSACTIONS:

Following are transactions that took place during the quarter ending December 30, 2006:

- a.** On October 12, 2006 50,000 options were granted under the Stock Option Plan to a new member of the scientific advisory board, an outside party. The exercise price has been determined at \$0.65 per share, which was equivalent to the traded market price on the date of grant.

The options may be exercised after vesting and only in accordance with the following:

1. On the first anniversary commencing the grant date - 25% of the options.
2. On the last day of each of the 36 months following the first anniversary of the grant date, the remaining options shall vest in equal monthly installments

The fair value of the above options is estimated by using Black Scholes option-pricing model as \$15,553, and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 91%; risk-free interest rates of 4.65%; and expected lives of 7.88 years.

- b.** On October 18, 2006 the Company entered into a Strategic Alliance Agreement with UTEK Corporation (“UTEK”), pursuant to which UTEK would assist the Company in identifying technology acquisition opportunities. Per the agreement in consideration for the services being provided to the Company by UTEK, the Company shall pay \$120,000 in the form of 171,432 unregistered shares of common stock. The Company had the option of paying UTEK \$10,000 per month. The Company has agreed to issue UTEK an aggregate of 171,432 shares of common stock, par value \$0.0001 per share, of the Company, which will vest in 12 equal monthly instalments of 14,286 shares. If the agreement is terminated any unvested shares will be returned to the Company.

The shares presented in the statement of changes in shareholders equity represent issued shares in respect of service received up to December 31, 2006, since the rest of the shares are not considered issued for accounting purposes.

- c.** On November 13, 2006 150,000 options were granted under the Stock Option Plan to each of the Company’s two board members who joined the board on November 6, 2006 (total - 300,000 options).

The exercise price has been determined at \$0.45 per share, which was equivalent to the traded market price on the date of grant.

The options may be exercised after vesting and only in accordance with the following:

1. On the first anniversary commencing the grant date - 25% of the options.
2. On the last day of each of the 36 months following the first anniversary of the grant date, the remaining options shall vest in equal monthly installments

The fair value of the above options on the date of grant was estimated by using Black Scholes option-pricing model as \$111,859, and was based on the following assumptions: dividend yield of 0%; expected volatility of 90%; risk-free interest rates of 4.65%; and expected lives of 7.88 years.

GAMMACAN INTERNATIONAL INC.
(A Development Stage Company)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

NOTE 4 - STOCK TRANSACTIONS (continued):

d. On December 5, 2006 50,000 options were granted under the Stock Option Plan to a new member of the scientific advisory board, an outside party. The exercise price has been determined at \$0.50 per share, which was equivalent to the traded market price on the date of grant.

The options may be exercised after vesting and only in accordance with the following:

1. On the first anniversary commencing the grant date - 25% of the options.
2. On the last day of each of the 36 months following the first anniversary of the grant date, the remaining options shall vest in equal monthly installments

The fair value of the above options is estimated by using Black Scholes option-pricing model as \$16,138, and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 90%; risk-free interest rates of 4.65%; and expected lives of 7.88 year

NOTE 5 -SUBSEQUENT EVENT:

1. On January 30, 2007, Gammacan, Ltd., a subsidiary of the Company (the "Subsidiary") entered into a Master Services Agreement with BioSolutions Services, LLC ("BioSolutions"), pursuant to which the subsidiary will from time-to-time engage BioSolutions for various projects to assist the Corporation with the commercialization of its anti-cancer immunotherapy to treat metastatic cancer. The services to be performed under the Master Services Agreement will be specified in separate work orders, which will set forth the scope of the work, schedule and costs.

Work order 1 relates to regulatory consulting services to be provided by Biosolutions in connection with the application for an IND with the US FDA for VitiGam. As compensation for the services the Subsidiary will pay BioSolutions a cash fee between \$170,000 to \$290,000 based on several factors, and the Company will issue to BioSolutions a warrant to purchase 434,783 shares of its common stock at a purchase price of the lower of \$0.48 per share or the average trading price of the preceding 30 days from the date of grant. The warrant shall be vested as follows: 1) 33% upon signature of a definitive agreement with a manufacturer, 2) 33% upon IND filing and 3) 34% when IND has been approved by the FDA.

2. On February 1, 2007 the Subsidiary entered into a Cooperation and Project Funding Agreement with Cooperation and Project Funding (the "BIRD Foundation") and Life Therapeutics ("Life"), pursuant to which the BIRD Foundation will provide the Subsidiary and Life with funding of the lesser of \$1,000,000 or 50% of expenditures on the development of an anti-cancer immunotherapy to treatment for metastatic cancer. The funding will be repaid to the BIRD Foundation if the development work goes beyond a Phase 2 clinical trial.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF PLAN OF OPERATION

As used in this current report, the terms "we", "us", "our", "the Company" and "GammaCan" mean GammaCan International, Inc. and our subsidiary, GammaCan, Ltd., unless otherwise indicated.

All dollar amounts refer to US dollars unless otherwise indicated.

We are a development stage Company and currently have no revenue from operations. Other than existing cash reserves and our intellectual property we have no significant assets, tangible or intangible. There can be no assurance that we will generate revenues in the future, or that we will be able to operate profitably in the future, if at all. We have incurred net losses in each fiscal year since inception of our operations.

Plan of Operation

Short Term Business Plan

Our initial focus over the next several years is to demonstrate efficacy of Immunoglobulin G ("IgG") cancer immunotherapy in human clinical trials. Efficacy is the ability of a drug or other treatment to produce the desired result when taken by its intended users. If ultimately proven to be successful, and there can be no assurance that it will be, we could be well-positioned to enter a licensing agreement with a major pharmaceutical partner for commercial market development and sales.

IgG immunotherapy will require regulatory approval before being commercially marketed for human therapeutic use. Clinical trials generally include three phases that together may take several years to complete. Phase 1 clinical studies (toxicity trials) are primarily conducted to establish the safety and determine the maximally tolerated dose (MTD). Phase 2 studies are designed to determine preliminary efficacy and establish dosing. Phase 3 studies are conducted to optimize therapeutic efficacy in a statistically significant manner at the levels of optimal dose, method of delivery into the body or route, and schedule of administration. Once clinical trials are completed successfully, products may receive regulatory approval.

Since July 2005, we have been conducting a Phase 2 clinical trial in humans to demonstrate clinical efficacy of IgG immunotherapy in three major cancers: colon, prostate and melanoma. To date, 32 patients have been enrolled, out of which 27 have actually received the IgG treatment. This phase 2 clinical trial is being conducted at three medical centers in Israel and results will likely be available during 2007. The trial is due to be completed during 2007. We may continue to monitor patients for a number of years after the trial in order to collect additional evidence of efficacy and potential benefits or adverse effects of the IgG treatment. If successful or promising, and at this preliminary stage there is no assurance they will be, results of these clinical trials may be used to enter into discussions with a major pharmaceutical partner and plasma based product manufacturers to work with us to potentially commercialize this IgG product. This commercialization will include the need to conduct Phase 3 clinical trials in accordance with local regulatory requirements. Such trials may be long-term trials and may require substantial financial resources that we do not presently possess.

We are also in the process of applying for an Investigational New Drug Application ("IND") with the US FDA for VitiGam, GammaCan's second generation IgG product and first-in-class anti-cancer immunotherapy. We expect that VitiGam will enter the clinic under a US IND with in the next 12 months. VitiGam is designed to target metastatic melanoma patients with stage III and IV melanoma.

VitiGam is an intravenous IgG mixture derived from IgG manufactured from plasma collected from donors with vitiligo, a benign autoimmune skin condition affecting up to 2% of the general population. GammaCan scientists have shown that vitiligo derived IgG (VitiGam) contains anti-melanoma activities in substantially higher quantities than those found in IgG from other donors. This “enriched” vitiligo IgG (VitiGam) has potent anti-melanoma activity in both *in vitro* and *in vivo* melanoma models. Preliminary data from the ongoing, open-label Phase 2 trial of GCAN 101 (“standard” IgG) in melanoma patients further support the rationale underling the VitiGam program.

The Company intends to conduct a Phase 1/2 trial under a US IND to evaluate VitiGam in patients with stage III and IV melanoma. As described under the Planned Expenditure section, the estimated costs of this Phase 1/2 are substantial; the timing of initiation of the Phase 1/2 trials will be based on several major factors, including the ability of the Company to attract sufficient financing on acceptable terms.

We are also contemplating conduct additional clinical trials to test new formulations and/or combinations of IgG and to test IgG immunotherapies for different cancers at different stages of disease progression with varying dosages and routes of administration. To achieve this we may elect to partner with a pharmaceutical company to conduct these further clinical trials, in order to attain broad-based regulatory approval.

We expect that it will take a number of years to receive final approval and registration of an IgG preparation for use as an anti-cancer agent. The Company's strategy is to collaborate with a suitable partner to support late stage (Phase 3) clinical development, registration and sales for its IgG based cancer products.

Long Term Business Strategy

As noted previously, if our IgG base cancer immunotherapies show significant promise through clinical trials, we plan to ultimately seek a strategic commercial partner, or partners, with extensive experience in the commercialization and marketing of cancer drugs and or other infused therapeutic proteins. It is envisioned that the partner, or partners, would be responsible or substantially support late stage clinical trials (Phase 3) to ensure regulatory approvals and registrations in the appropriate territories in a timely manner. It is further envisioned that the partner, or partners, would be responsible for sales and marketing of our IgG immunotherapies in certain agreed upon territories. Such planned strategic partnership, or partnerships, could provide a marketing and sales infrastructure for our products as well as financial and operational support for global trials and other regulatory requirements concerning future clinical development in the US and elsewhere. Our future strategic partner, or partners, could also provide capital and expertise that would enable the partnership to develop new formulations of IgG cancer immunotherapy suitable for patients at different stages of disease progression as well as IgG derivatives. Under certain circumstances, the Company may decide to develop any of its IgG based cancer immunotherapies on its own, either world wide or in select territories.

Other Research and Development Plans

In addition to conducting early-stage clinical trials, we plan to conduct pre-clinical research to further deepen our understanding of the biology of our IgG products in cancer, develop alternative delivery systems, to determine the optimal dosage for different patient groups, to investigate alternative sources of immunoglobulin other than human plasma, to develop novel IgG based therapies and to develop successor products to our current products. For example, we plan to conduct research to isolate the fraction of IgG, which is responsible for its anti-metastatic effects and to develop a potential synthetic version of IgG. These formulations will be suitable for:

Low-dose, preventative therapy for disease-free, high-risk individuals,
Strong dose for use in conjunction with surgery and other cancer treatments, and
Maintenance dose for use to prevent recurrence of cancer growth.
Others

Our plan is to patent any successful inventions resulting from our future research activities and to exploit any other means that may exist to protect our future IgG anti-cancer therapies in the commercial markets. For example, we may seek Orphan Drug Status for future IgG anti-cancer therapies for certain indications in certain markets.

Other Strategic Plans

In addition to developing our own IgG based anti-cancer therapies drug portfolio, we are considering in-licensing and other means of obtaining additional lead molecules of technologies to complement and/or expand our current product portfolio. The goal of this is to create a well-balanced product portfolio including lead molecules in different stages of development and addressing different medical needs.

Critical accounting policies and estimates

Management's discussion and analysis of the financial condition and results of operations is based upon the consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates and judgments. We base our estimates on various factors, including historical experience that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other resources. Actual results may differ from these estimates under different assumptions or conditions.

We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.

Going concern assumption

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has net losses for the period from inception (October 6, 1998) through December 31, 2006 of \$4,584,828, as well as negative cash flow from operating activities. Presently, the company does not have sufficient cash resources to meet its requirements in the twelve months following January 1, 2007. These factors raise substantial doubt about the company's ability to continue as a going concern. Management is in the process of evaluating various financing alternatives as the Company will need to finance future research and development activities and general and administrative expenses through fund raising in the public or private equity markets. Although there is no assurance that the Company will be successful with those initiatives, management is confident that it will be able to secure the necessary financing as a result of ongoing financing discussions with third party investors and existing shareholders.

The financial statements do not include any adjustments that may be necessary should the company be unable to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to obtain additional financings as may be required and ultimately to attain profitability.

Valuation of options and warrants

The Company granted options to purchase common shares of our company to employees and consultants and issued warrants in connection with fund raising.

Until September 30, 2006 the Company accounted for employee stock based compensation in accordance with Accounting Principles Board Opinion No. 25 "Accounting for Stock Issued to Employees" ("APB 25") and related interpretations. In accordance with FAS 123 - "Accounting for Stock-Based Compensation" ("FAS 123"), the Company disclosed pro forma data assuming the Company had accounted for employee stock option grants using the fair value-based method defined in FAS 123.

On October 1, 2006 the Company adopted the revised Statement of Financial Accounting Standards ("FAS") No. 123, *Share-Based Payment* (FAS 123R), which addresses the accounting for share-based payment transactions in which the Company obtains employee services in exchange for (a) equity instruments of the Company or (b) liabilities that are based on the fair value of the Company's equity instruments or that may be settled by the issuance of such equity instruments. FAS 123R eliminates the ability to account for employee share-based payment transactions using APB Opinion No. 25, *Accounting for Stock Issued to Employees*, and requires instead that such transactions be accounted for using the grant-date fair value based method. This Statement is effective as of the beginning of the first annual reporting period that begins after December 15, 2005, for small business issuers, which is October 1, 2006 for the Company.

FASB 123R applies to all awards granted or modified after the Statement's effective date. In addition, compensation cost for the unvested portion of previously granted awards that remain outstanding on the Statement's effective date shall be recognized on or after the effective date, as the related services are rendered, based on the awards' grant-date fair value as previously calculated for the pro-forma disclosure under FAS 123.

The Company applied the modified prospective application transition method, as permitted by the Statement. Under such transition method, upon the adoption of FAS 123R, the Company's financial statements for periods prior to the effective date of the Statement is not restated.

The company accounts for equity instruments issued to third party service providers (non-employees) in accordance with the fair value based on an option-pricing model, pursuant to the guidance in EITF 96-18 "Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling Goods or Services". The fair value of the options granted is revalued over the related service periods and recognized using the accelerated method.

Deferred income taxes

Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.

Regarding the Israeli subsidiary, paragraph 9(f) of FAS 109, "Accounting for Income Taxes", prohibits the recognition of deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities.

Results of Operations

Three months ended December 31, 2006 and 2005

The following table summarizes certain statement of operations data for the company for the three months period ended December 31, 2006 and 2005 (in US\$):

	Three months ended December 31,	
	2006	2005
Research and development costs	\$ 167,972	\$ 225,161
General and administrative expenses	637,222	212,775
Financial expenses (income), net	2,221	(5,022)
Net loss for the period	\$ (807,415)	\$ (432,914)

Research and development costs.

Research and development expenses are the costs incurred in the process of our pre-clinical and our clinical trials. Clinical trial and pre-clinical expenses include regulatory consultants and fees, research expenses, purchase of plasma, the cost of manufacturing IgG and payments to medical centers for patient recruitment and treatment.

During the three months ended December 31, 2006 and December 31, 2005 the research and development expenses included, among others, the clinical trial and pre-clinical trial expenses, the consultants compensation, costs related to the registered patents as well as salaries and related expenses.

During the three months ended December 31, 2006 the research and development expenses totaled \$167,972, compared to \$225,161 during the three months ended December 31, 2005. The decrease in cost is attributable to the final stages of the Phase 2 clinical trial we are currently conducting.

General and administrative expenses

The general and administrative expense includes the salaries and related expenses of the company's management, consulting, legal and professional fees, traveling, business development costs as well as insurance expenses.

For the three months ending December 31, 2006 the General and administrative expenses totaled \$637,222 compared to \$212,775 for the three months ended December 31, 2005. Costs incurred related to general and administrative activities in the three months ended December 31, 2006 reflect an increase in the number of employees as compared to the three months period ending December 31, 2005. During the three months ended December 31, 2006 the company incurred \$348,751 of costs due to the implementation of FAS 123R related to stock options granted to employees, \$329,542 of these costs were classified to the General and administrative expenses. The company did not incur similar costs in the three months ended December 31, 2005.

Financial income/expense, net

During the three months ending December 31, 2006 and December 31, 2005, the company generated interest income on available cash and cash equivalents balance and incurred interest expenses related to its issued convertible promissory note.

Liquidity and Capital Recourses

Financing activities

Through December 31, 2006, the Company has incurred losses in an aggregate amount of \$4,584,828. We have financed our operation from private placement of common stock and loans received. Through December 31, 2006 we raised a total of \$3,652,829, net of transaction cost, through private placements and received a total of \$350,000 in loans and we anticipate that additional financing will be through similar sources. Our financing activities for the three months period ending December 31, 2006 include the following:

On November 20, 2006 the Company issued a convertible promissory note, aggregate principal amount of \$350,000, which bears interest at 8% payable on maturity of the note and matures on November 20, 2007.

Employee's stock options plan

On October 12, 2006 we granted options to purchase up to 50,000 common shares of our company at an exercise price of \$0.65 to a new member of our Scientific Advisory Board.

On November 13, 2006 we granted options to purchase up to 150,000 common shares of our company at an exercise price of \$0.45 to each of Steven Katz and Albert Passner, its two new Board members. Total options granted to purchase 300,000 common shares were granted.

On December 5, 2006 we granted options to purchase up to 50,000 common shares of our company at an exercise price of \$0.50 to a new member of our Scientific Advisory Board.

Planned Expenditures

The estimated expenses referenced herein are in accordance with our business plan. As the technology is still in the development stage, it can be expected that there will be changes in some budgetary items. Our planned expenditures for the next 12 months include:

Category	Amount
Research & Development	4,045,000
General & Administrative Expenses	2,078,000
Finance income, net	(49,000)
Total	6,074,000

As previously indicated we are in the process of applying for an IND with the US FDA for VitiGam, GammaCan's second generation IgG based product and first-in-class anti-cancer immunotherapy. VitiGam is slated to enter the clinic trial phase pursuant to a US IND. VitiGam is designed to target metastatic melanoma patients with stage III and IV melanoma. Our ability to proceed with the IND application as well as the commencement of the required clinical trial is dependent on several major factors one of which is the ability to attract sufficient financing on acceptable terms.

Related party transactions

Mr. Yair Aloni, a director of our company, and Professor Yehuda Shoenfeld, M.D., the Chief Scientist of our subsidiary, GammaCan, Ltd., are authorized signatories of ARP Biomed Ltd. for the Intellectual Property Purchase and Sale Agreement we entered into with ARP Biomed Ltd. on June 11, 2004. Mr. Aloni is the Chief Executive Officer of ARP and Mr. Shoenfeld is an advisor to ARP.

On June 6, 2005, the Company and GammaCan, Ltd. appointed Vered Caplan as acting Chief Executive Officer of both companies, effective July 2, 2005. Vered Caplan will devote approximately 70% of her business time to the affairs of GammaCan, Ltd. and the Company. Vered Caplan shall receive a salary of \$6,475 per month. On April 15, 2006 Vered Caplan has resigned from her position as the acting Chief Executive Officer of the company. Vered Caplan will remain as the Chief Executive Officer of GammaCan, Ltd.

On April 16, 2006, the Company entered into an employment agreement (the "Agreement") with Patrick Schnegelsberg pursuant to which Mr. Schnegelsberg will serve as Chief Executive Officer of the Company, effective April 15, 2006. Mr. Schnegelsberg shall receive a salary of \$200,000 and an annual bonus of up to \$200,000 upon achieving certain objectives. Pursuant to a separate agreement between the Company and Mr. Schnegelsberg, the Company agreed to indemnify Mr. Schnegelsberg for substantially all liabilities he may incur as a result of his employment by or service to the Company. Mr. Schnegelsberg was granted 1,400,000 stock options of the Corporation, pursuant to the Corporation's 2004 Stock Option Plan, adopted by the Board on August 17, 2004. Options are exercisable at an exercise price of \$1.29 per share. 350,000 of the Options shall vest on the first anniversary from their date of grant, and the remaining Options shall vest in 36 equal monthly instalments thereafter.

ITEM 3. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures. As of December 31, 2006, the Company's management carried out an evaluation, under the supervision of the Company's Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Company's system of disclosure controls and procedures (as defined by Rule 13a-15(e) and 15d-15(e) under the Security and Exchange Act of 1934, as amended ("the Exchange Act"). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective, as of the date of their evaluation, for the purposes of recording, processing, summarizing and timely reporting material information required to be disclosed in reports filed by the Company under the Exchange Act.

Changes in internal controls. There were no changes in the Company's internal controls over financial reporting, that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.

PART II

ITEM 1 LEGAL PROCEEDINGS

From time to time the Company is subject to litigation incidental to its business. Such claims, if successful, could exceed applicable insurance coverage. The Company is not currently a party to any material legal proceedings.

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On October 18, 2006 the Company entered into a Strategic Alliance Agreement with UTEK Corporation (“UTEK”), pursuant to which UTEK would assist the Corporation in identifying technology acquisition opportunities. As consideration for the services being provided to the Corporation by UTEK, the Corporation has agreed to issue UTEK an aggregate of 171,432 shares of common stock, par value \$0.0001 per share, of the Corporation, which will vest in 12 equal monthly instalments of 14,286 shares.

ITEM 3 DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Not applicable.

ITEM 5 OTHER INFORMATION

Not applicable.

ITEM 6 EXHIBITS

31.1 - Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended

31.2 - Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as amended

32.1 - Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)

32.2 - Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GAMMACAN INTERNATIONAL, INC.

February 9, 2007

/s/ CHAIME ORLEV
Chaime Orlev,
Chief Financial Officer